Rahmat Afrasiabi, MD
Allergy · Prescott, AZNPI 1811961204
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by GSK at 50.9% of the total. 2025 is the largest year on record at $183, more than ten times the $12 reported in 2020.
Across 12 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$107
- Novartis$55
- Grifols USA, LLC$21
- AstraZeneca$16
- Boston Scientific$12
What the payments were for
- Food & beverage$211100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $107 |
| Novartis | 3 | $55 |
| Grifols USA, LLC | 1 | $21 |
| AstraZeneca | 1 | $16 |
| Boston Scientific | 1 | $12 |
How this compares
Too few allergy providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 35 | $104,941 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $102,913 |
| Dupixent SyringeDupilumab | 28 | $102,170 |
| Epinephrine | 108 | $19,723 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $4,736 |
| Cromolyn Sodium | 25 | $2,984 |
| Famotidine | 149 | $2,462 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $1,958 |
| Ipratropium Bromide | 43 | $1,294 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $1,152 |
| Montelukast Sodium | 130 | $590 |
| Hydroxyzine Hcl | 20 | $320 |
| Fluticasone Propionate | 20 | $225 |
| Levocetirizine Dihydrochloride | 16 | $151 |
| Clobetasol Propionate | 13 | $131 |
Paid to pharmacies, not to this prescriber.
Other allergy in Prescott
- Todd HrabakGlendale$401K
- Jodi RubinScottsdale$30K
- Julie WendtScottsdale$16K
- Allan WachterPhoenix$4K
- Hugh MackechnieScottsdale$413
- Richard KeightleyPhoenix$402
- Eddie GainesAnthem$44
- Linda Alvarez ThullScottsdale$24
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.